Cipla Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/u84jm3tm3anx5otlo6j0bih3.pdf

Key Takeaways


Margin Performance & FY25 Guidance

Umang Vohra: "we are also constrained by the inability to launch several products from our facilities due to their citation. And some of these products are fairly — can be fairly material to the trajectory of this — of our company."

One-India: Branded Prescription & Trade Generics

Umang Vohra: "We don't see more than a 20% overlap between what sells in the Tier 2 to 6 cities in our generics business versus what sells in these cities from our Rx or Prescription business."

North America: Record Revenue, Facility Overhang

Umang Vohra: "please keep in mind that inspection needs to happen, then there is a 90-day process post inspection for a company to respond and then the EIR comes and then the asset has to be approved. So you just factor that time line, it's very sensitive to when the plant is audited."

Pipeline, Launches & Manufacturing


International Markets & Partnerships


Capital Allocation & Inorganic Strategy


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin24.5% to 25.5%, up ~200 bps YoY; not contingent on Goa clearanceFY25
R&D expense ratio6% to 7% of revenueFY25
Peptide launchesLaunch 4 peptide assets, including a "largish" one in Q1FY25
China respules supplies to USBegin supplies from newly approved China facilityH2 FY25
Respiratory filingsFile 2 respiratory assets with significant revenuesNext 12–15 months
Advair generic launchLaunch toward end of fiscal year, dependent on DPI line readinessFY25 end
Biosimilar asset launchEnter Phase I soon, launch thereafter~2030
Trade Generics model transitionImpact for a quarter, recover over the yearFY25
Goa reinspectionReinspection likely around July/August or beyond; asset progression assumed in later half of FY25H2 FY25

Key Metrics

MetricQ4 FY24
Revenue₹6,163 cr, +10% YoY
FY24 revenue₹25,455 cr, +14% YoY
EBITDA margin21.4%, vs 20.45% last year, ~100 bps improvement
FY24 EBITDA margin24.5%, vs 22.2% last year, 200 bps improvement
Gross margin after material costs66.7%, 192 bps over last year
FY24 gross margin66%, higher by 200 bps YoY
Profit after tax₹939 cr, 15% of sales, ETR at 25.8%
FY24 profit after tax₹4,106 cr, 16% of sales, ETR at 27.1%
R&D investments₹444 cr, 7.2% of revenue, +19% vs last year
FY24 R&D investments₹1,571 cr, 6.2% of revenue
FY25 EBITDA margin guidance24.5% to 25.5%, up 200 bps over FY24
North America annual revenue$906 mn, +24% over previous year
One-India FY24 growth10%, propelled by Branded Prescription and Trade Generics
Lanreotide market share20.8%, as per IQVIA Feb '24
Albuterol market share15.5%, as per prescription data for April '24, up from 12% to 13% at year end
South Africa secondary growth11.2% YoY, vs market growth of 2.1% as per IQVIA MAT March '24
Chronic therapies share61% of portfolio, higher by ~100 bps YoY, grew 10% YoY vs IQVIA MAT March '24
ROIC~31% for FY24
Cash equivalent balance₹8,267 cr
Gross debt₹559 cr, includes lease liabilities and working capital facilities
FY24 capital investments₹1,315 cr, 70% towards growth, balance for maintenance
FY25 planned capital investments₹1,500 cr
Dividend per share~₹13, stepped up from ₹8.5
Respiratory share of global revenue~30%